ARCUS BIOSCIENCES INC (RCUS:NYSE)
$23.8 0.5 (2.1459%)
Analysed ARCUS BIOSCIENCES INC (RCUS:NYSE) News Sources
Arcus Biosciences, Inc. Q1 2026 Earnings Call Summary
06-05-2026
moby.co
Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift
06-05-2026
yahoo.com
Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report
08-05-2026
yahoo.com
Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts
16-05-2026
yahoo.com
How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook
21-05-2026
yahoo.com
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
26-05-2026
yahoo.com
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
03-06-2026
yahoo.com
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
04-06-2026
yahoo.com
Arcus Biosciences Announces New Employment Inducement Grants
09-06-2026
yahoo.com
Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story
12-06-2026
yahoo.com
What is the current price of ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The current price of ARCUS BIOSCIENCES INC (RCUS:NYSE) is $23.8.
ARCUS BIOSCIENCES INC (RCUS:NYSE) absolute price change since previous trading day?
The absolute price change of ARCUS BIOSCIENCES INC (RCUS:NYSE) since the previous trading day is $0.5.
ARCUS BIOSCIENCES INC (RCUS:NYSE) percentage price change since previous trading day?
The percentage price change of ARCUS BIOSCIENCES INC (RCUS:NYSE) since the previous trading day is 2.1459%.
What is the most recent average sentiment score for ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The most recent average sentiment score for ARCUS BIOSCIENCES INC (RCUS:NYSE) is 71 out of 100.
What is the most recent average sentiment for ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The most recent sentiment for ARCUS BIOSCIENCES INC (RCUS:NYSE) is .
SEC-8K** Filing Available For ARCUS BIOSCIENCES INC (RCUS:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.